Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013.

scientific article published on 29 June 2015

Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1093/INFDIS/JIV342
P698PubMed publication ID26123561

P50authorAllison L. NalewayQ37377682
Elizabeth R. UngerQ41636563
Sheila WeinmannQ89443286
Lauri E MarkowitzQ96186181
Martin SteinauQ114417639
P2093author name stringEileen F Dunne
Ning Smith
Jim Braxton
Bradley Crane
P2860cites workAssessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional studyQ28245583
Epidemiologic classification of human papillomavirus types associated with cervical cancerQ29616213
Vaccine-type human papillomavirus and evidence of herd protection after vaccine introductionQ36128894
Reduction of HPV infections through vaccination among at-risk urban adolescentsQ36176699
Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in EnglandQ37503936
Post-licensure monitoring of HPV vaccine in the United StatesQ37699644
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysisQ38037763
Population impact of HPV vaccines: summary of early evidenceQ38164983
Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impactQ45077291
Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006.Q45251131
Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.Q51871950
P433issue12
P407language of work or nameEnglishQ1860
P921main subjectcervix uterine cancerQ160105
HPV vaccineQ900189
P304page(s)1970-1975
P577publication date2015-06-29
P1433published inJournal of Infectious DiseasesQ4051141
P1476titleReduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013.
P478volume212

Reverse relations

cites work (P2860)
Q47921143Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study.
Q92499094Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination
Q97565439Evidence of HPV vaccination efficacy comes from more than clinical trials
Q59349018Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program
Q38671633Functional assessment and structural basis of antibody binding to human papillomavirus capsid
Q57463921Human Papillomavirus Prevalence Among American Indian Women of the Great Plains
Q47257772Impact of HPV vaccination with Gardasil® in Switzerland
Q50091385Monitoring the impact of HPV vaccine in males-Considerations and challenges
Q37288157Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes
Q78879005Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Q36987575The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis
Q64136607Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015

Search more.